Hematologic findings. Median platelet counts (A), WBC counts (B), and hemoglobin levels (C) over time beginning at week 8 are displayed by ruxolitinib average total daily dose among patients treated with a starting dose of 25 mg twice daily. Error bars are interquartile ranges. The proportion of patients with platelet counts >400 × 109/L at baseline and ≤400 × 109/L after baseline (D) and platelet counts >600 × 109/L at baseline and ≤600 × 109/L after baseline (E) are displayed by ruxolitinib average total daily dose among patients treated with a starting dose of 25 mg twice daily. (F) Median percentage change from baseline in JAK2V617F allele burden includes all patients regardless of ruxolitinib starting dose to ensure a sufficiently large patient population. Time points that included data from <5 patients were excluded. Allele burden was assessed with a quantitative real-time polymerase chain reaction assay; JAK2V617F-negative samples were confirmed by a quantitative single-nucleotide extension assay.
